RxGrab · Drug pricing tool · CMS NADAC read 11 November 2026
Try one
Example result. Open Atorvastatin as its own page
Generic
$0.128 per unit at the 2013 year-end survey (23 NDCs) and $0.023 at the 2026 survey (70 NDCs): −82%.
Generic
$0.177 per unit at the 2013 year-end survey (23 NDCs) and $0.029 at the 2026 survey (69 NDCs): −84%.
2 more products are on the full page.
CMS National Average Drug Acquisition Cost, year-end surveys 2013 to 2026. A pharmacy acquisition cost, not a retail price. About NADAC.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the CMS pharmacy pricing page, year-end surveys 2013 to 2026 (latest 11 November 2026).
You read a drug's price history as a year-end median and a range, not a price tag.
The largest falls are generics that gained competition. Entecavir 0.5 MG Tablet went from $30.12 to $0.246 per unit between the 2014 and 2026 year-end surveys. The table shows the ten largest falls among products priced from at least 3 NDCs at both ends.
| Product | 2014 | 2026 | Change | NDCs priced |
|---|---|---|---|---|
| Entecavir 0.5 MG Tablet | $30.12 | $0.246 | −99% | 3 to 13 |
| Capecitabine 500 MG Tablet | $27.41 | $0.454 | −98% | 4 to 17 |
| Acyclovir 5% Ointment | $15.58 | $0.364 | −98% | 6 to 15 |
| Clomipramine 25 MG Capsule | $8.33 | $0.203 | −98% | 5 to 19 |
| Valsartan 80 MG Tablet | $3.01 | $0.081 | −97% | 3 to 17 |
| Fluocinonide 0.1% Cream | $10.38 | $0.285 | −97% | 12 to 6 |
| Clobetasol 0.05% Ointment | $4.93 | $0.137 | −97% | 12 to 36 |
| Clomipramine 50 MG Capsule | $8.29 | $0.252 | −97% | 5 to 19 |
| Temozolomide 20 MG Capsule | $27.14 | $0.880 | −97% | 6 to 15 |
| Mycophenolic Acid DR 360 MG Tb | $6.65 | $0.216 | −97% | 4 to 13 |
The largest rises are mostly brand products and a few older generics. The table shows the ten largest rises among products priced from at least 3 NDCs at both ends; a rise here says nothing about why.
| Product | 2014 | 2026 | Change | NDCs priced |
|---|---|---|---|---|
| Polyethylene Glycol 3350 Powd | $0.029 | $1.24 | +4196% | 15 to 37 |
| Isoniazid 100 MG Tablet | $0.066 | $1.73 | +2512% | 8 to 3 |
| Isoniazid 300 MG Tablet | $0.150 | $3.32 | +2115% | 16 to 9 |
| Naproxen DR 375 MG Tablet | $0.149 | $2.16 | +1353% | 3 to 3 |
| Naproxen DR 500 MG Tablet | $0.196 | $1.95 | +894% | 4 to 5 |
| Haloperidol Lac 2 MG/ML Conc | $0.043 | $0.414 | +867% | 5 to 6 |
| Prednisolone 15 MG/5 ML Soln | $0.063 | $0.540 | +752% | 6 to 11 |
| Fluoxetine 20 MG/5 ML Solution | $0.036 | $0.217 | +497% | 4 to 5 |
| Verapamil ER 120 MG Capsule | $0.531 | $2.92 | +449% | 4 to 3 |
| Clomiphene Citrate 50 MG Tab | $0.906 | $4.06 | +348% | 5 to 12 |
The most common mistake reads an acquisition-cost fall as a fall in the patient's price. The two are linked only loosely.
"The generic cost pharmacies 84% less, so my prescription should cost 84% less."
Read it as what the pharmacy pays. Your price adds a dispensing fee and margin and depends on your plan or card. Ask the pharmacy for its price and compare, and see the FDA generic drug facts for how generics are approved.
Any drug can be shown on another site as a self-sizing panel, free with the source line left in place.
<div data-drug-price-history data-drug="atorvastatin"></div>
<script async src="https://rxgrab.com/tools/drug-price-history/embed.js"></script>Set data-drug to the drug's key, the last part of its page address.
Type the medicine's name into the check. It shows, for each product, the year-end median per-unit acquisition cost from the CMS NADAC survey for every year from 2013, the lowest and highest NDC at each point, and how many NDCs were priced.
No. NADAC is the price pharmacies pay to acquire a drug. What you pay adds the pharmacy's dispensing fee and margin and depends on your insurance or discount card. The page reports acquisition cost and says nothing about your price.
The data does not say why a price moved. When more makers enter, or a patent ends, acquisition costs often fall, but this check records the price and the number of NDCs priced and does not assign a cause.
A comparison is marked thin when fewer than 3 NDCs were priced at one end. A median over one or two NDCs reflects which NDCs were priced as much as a price movement, so a large percentage on a thin comparison is not shown as a finding.
The check stores the last weekly survey of each year, so it shows year-end prices and not moves within a year. NADAC publishes weekly; the weekly files are on the CMS open data portal.
The CMS National Average Drug Acquisition Cost yearly datasets on data.medicaid.gov, 2013 to 2026. Public US government data. The latest survey week is 11 November 2026.
Yes. The embed code on this page shows any drug as a self-sizing panel, free to use with the source line left in place.
The check was built from the CMS NADAC yearly datasets under a method written and hashed before any change was published. Each year's last weekly survey is stored whole, every row lands in one product at one year end, and a test recomputes the medians for a random sample of 300 product-year points straight from the stored rows. The same code produces the result on this page, on each drug's page and in the embed. What the independent check found. The dataset behind it is published at doi:10.5281/zenodo.24182320. Further reading: the CMS pharmacy pricing page; the CMS open data portal; 42 CFR 447.512 on drug payment; the FDA generic drug facts; the FDA Orange Book; the FDA first generic approvals; the FDA drug shortages page; the NLM RxNav drug names service; the FDA National Drug Code directory; CMS.